Abstract: RNA interference is provided for inhibition of histamine receptor H1 mRNA expression, in particular, for treating patients having an HRH1-related condition or at risk of developing an HRH1-related condition such as allergic conjunctivitis, ocular inflammation, dermatitis, rhinitis, asthma, or allergy.

Abstract: RNA interference is provided for inhibition of Rho kinase mRNA expression for treating patients with ocular disorders, particularly for treating intraocular pressure, ocular hypertension and glaucoma. Rho kinase mRNA targets include mRNA for ROCK1 and ROCK2.

Abstract: A multi-sleeve handpiece for performing phacoemulsification with a vibratory, ported needle and for cooling an exterior of an incision. The vibratory, ported needle breaks up and aspirates broken eye tissue. The handpiece has at least one inner sleeve that guides irrigation fluid to the eye and/or reduces friction between the vibrating tool and the surrounding rigid sleeve or tissues. The handpiece has an outer, cooling sleeve that is concentric with the inner sleeve and the needle and whose distal end has peak and valley formations. The cooling sleeve is collapsible to engage incision tissue with the peak formations and allow the cooling fluid to flow across the valley formations to cool the tissue via heat transfer.

Abstract: Triamcinolone acetonide suspension compositions are disclosed. The suspension compositions have a relatively low viscosity and are easy to extrude through a 27- or 30-guage needle but are highly flocculated and easily redispersed. The compositions are particularly suitable for intravitreal injection.

Abstract: Methods of treating symptoms of dry eye by administering a fatty acid amide or inhibitors of fatty acid amide hydrolase (FAAH) are disclosed. Methods of preventing or alleviating ocular pain by administering a fatty acid amide or FAAH inhibitors are also disclosed.

Abstract: An accessory is adapted to removably couple to a laser source connector separate from a fiber connector. The accessory includes a first contact element configured to form an electrical connection to a first portion of the laser source connector. The accessory further includes a second contact element configured to form an electrical connection to a second portion of the laser source connector. The second portion of the laser source connector is electrically insulated from the first portion of the laser source connector. The accessory also includes a network connected to the first contact element and the second contact element. The network establishes a defined electrical characteristic between the first and second contact element when a fiber connector is connected to laser source connector.

Abstract: The present invention relates to processes for purifying guar comprising combining borate and guar in an aqueous solution and treating the aqueous solution with an organic solvent to induce precipitation of purified guar. Another embodiment of the present invention is directed to ophthalmic formulations comprising purified guar produced by the processes described.

Abstract: In one exemplary aspect, the present disclosure is directed to an assembly having an irrigation hand piece that includes an irrigation needle extending from a distal end. The irrigation needle is also configured to release a first fluid. The assembly further has an aspiration hand piece that includes an aspiration needle extending from a distal end. The aspiration needle has an axis and is configured to aspirate a second fluid into the assembly. The assembly has a first configuration in which the irrigation hand piece and aspiration hand piece are coupled together in a manner that causes the released first fluid from the assembly to flow coaxially about the axis of the aspiration needle and a second configuration in which the irrigation hand piece and aspiration hand piece are uncoupled which causes the released first fluid to flow substantially non-coaxial with respect to the axis of the aspiration needle.

Abstract: An implantable intraocular pressure sensor system has a sealed geometric shape with an internal pressure at a first value. A strain gauge wire is embedded in a surface of the sealed geometric shape. When the surface is deflected by intraocular pressure, a measured resistance of the strain gauge wire indicates the intraocular pressure. The system also has a processor coupled to a power source and memory. The processor is configured to read the measured resistance and write values corresponding to intraocular pressure to the memory.

Abstract: Disposable injection devices are disclosed herein. In an exemplary arrangement, the disposable injection device comprises an annular sleeve, a predetermined pre-injection quantity of a substance configured for selective injection, and a temperature control element. The annular sleeve at least partially defines a dispensing chamber therein. The predetermined pre-injection quantity of the substance configured for selective injection is disposed within the dispensing chamber. The temperature control element is operably connected to the dispensing chamber, and is configured to selectively heat the substance to a predetermined temperature. The substance expands from the pre-injection quantity at the predetermined temperature to an injection quantity whereby the injection quantity is greater than a volume defined by the dispensing chamber. In this manner, a predetermined minimum quantity of the substance is self-expelled from the dispensing chamber.

Abstract: The present invention is directed to the provision of pharmaceutical compositions. The compositions include a therapeutic agent and a relatively low amount of surfactant for providing higher bioavailability of the therapeutic agent. The compositions are particularly desirable as ophthalmic compositions in which the therapeutic agent is a prostaglandin such as travoprost and the surfactant is a vegetable oil such as castor oil.

Abstract: An ophthalmic pharmaceutical composition useful in the treatment of glaucoma and control of intraocular pressure comprising an effective amount of a selective modulator of ALK5 receptor activity is disclosed. Also disclosed is a method of treating glaucoma and controlling intraocular pressure comprising applying a therapeutically effective amount of a pharmaceutical composition comprising a selective modulator of ALK5 receptor activity to an affected eye of a patient.

Abstract: Triamcinolone acetonide suspension compositions are disclosed. The suspension compositions have a relatively low viscosity and are easy to extrude through a 27- or 30-gauge needle but are highly flocculated and easily redispersed. The compositions are particularly suitable for intravitreal injection.

Abstract: Triamcinolone acetonide suspension compositions are disclosed. The suspension compositions have a relatively low viscosity and are easy to extrude through a 27- or 30-gauge needle but are highly flocculated and easily redispersed. The compositions are particularly suitable for intravitreal injection.

Abstract: A method of operating an ultrasonic handpiece by pulsing the power supplied to the handpiece and varying the type of vibration during the power pulse.

Abstract: The invention provides methods for treating and/or preventing ocular disorders associated with increased intraocular pressure comprising administering a non-peptide bradykinin agonist to a patient in need thereof.

Abstract: Topical ophthalmic and otic solution compositions of moxifloxacin and dexamethasone phosphate are disclosed.

Abstract: The invention concerns in one embodiment a method of treating glaucoma or elevated intraocular pressure comprising administering a pharmaceutically effective amount of a composition comprising at least one prenyltransferase inhibitor. In another embodiment, the invention concerns a composition for the treatment of elevated intraocular pressure and glaucoma comprising a pharmaceutically effective amount of a prenyltransferase inhibitor.

Abstract: The present invention relates to fluoroquinolone derivatives having enhanced ocular penetration characteristics and/or antimicrobial activity, and to compositions comprising such derivatives. The derivatives and compositions are particularly well suited for treating ophthalmic bacterial infections. The present invention more particularly relates to the discovery that a 2-methyl substitution on a diazabicyclo group attached to a fluoroquinolone ring system produces improved permeability characteristics, and that a 5-amino substitution on a fluoroquinolone ring system results in improved anti-microbial activity.

Abstract: The present invention relates to novel silicon-based polymers, particularly silicon-based polymers having citrate groups, and their use as chelating agents, for forming nanostructures, as surfactants, as reducing agents and as stabilizers.